Abstract
Primary Sclerosing Cholangitis (PSC) is a chronic cholestatic disease characterized by hepatic inflammation and obliterative fibrosis, resulting in both intra- and extra-hepatic bile duct strictures. End-stage liver disease and bile duct carcinoma represent frequent complications. Incidence and prevalence of PSC in USA have been recently estimated as 0.9 per 100,000 person-years, and 1-6 per 100,000 person-years, respectively. Major diagnostic criteria include the presence of multifocal strictures, beadings of bile ducts, and compatible biochemical profile, once excluded secondary causes of cholangitis. Since the aetiology of PSC remains poorly defined, medical therapy is currently limited to symptom improvement and prolonged survival. Ursodeoxycholic acid (UDCA), corticosteroids and immunosuppressants have been proposed alone or in combination to improve the clinical outcome. In selected cases, surgical or endoscopic procedures need to be considered. Orthotopic liver transplantation (OLT) is at the moment the only definitive approach although disease relapse has been reported In this article the state of the art in PSC treatment and future promises in this field are reviewed.
Keywords: Liver, cirrhosis, inflammation, UDCA, immunosuppressant, IBD, cholestasis, biliary obstruction
Current Medicinal Chemistry
Title: Current Treatments of Primary Sclerosing Cholangitis
Volume: 14 Issue: 19
Author(s): M. Vacca, M. Krawczyk, M. Petruzzelli, R.C. Sasso, K.J. van Erpecum, G. Palasciano, G.P. vanBerge-Henegouwen, A. Moschetta and P. Portincasa
Affiliation:
Keywords: Liver, cirrhosis, inflammation, UDCA, immunosuppressant, IBD, cholestasis, biliary obstruction
Abstract: Primary Sclerosing Cholangitis (PSC) is a chronic cholestatic disease characterized by hepatic inflammation and obliterative fibrosis, resulting in both intra- and extra-hepatic bile duct strictures. End-stage liver disease and bile duct carcinoma represent frequent complications. Incidence and prevalence of PSC in USA have been recently estimated as 0.9 per 100,000 person-years, and 1-6 per 100,000 person-years, respectively. Major diagnostic criteria include the presence of multifocal strictures, beadings of bile ducts, and compatible biochemical profile, once excluded secondary causes of cholangitis. Since the aetiology of PSC remains poorly defined, medical therapy is currently limited to symptom improvement and prolonged survival. Ursodeoxycholic acid (UDCA), corticosteroids and immunosuppressants have been proposed alone or in combination to improve the clinical outcome. In selected cases, surgical or endoscopic procedures need to be considered. Orthotopic liver transplantation (OLT) is at the moment the only definitive approach although disease relapse has been reported In this article the state of the art in PSC treatment and future promises in this field are reviewed.
Export Options
About this article
Cite this article as:
M. Vacca , M. Krawczyk , M. Petruzzelli , R.C. Sasso , K.J. van Erpecum , G. Palasciano , G.P. vanBerge-Henegouwen , A. Moschetta and P. Portincasa , Current Treatments of Primary Sclerosing Cholangitis, Current Medicinal Chemistry 2007; 14 (19) . https://dx.doi.org/10.2174/092986707781368388
DOI https://dx.doi.org/10.2174/092986707781368388 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer Molecular Imaging: Radionuclide-Based Biomarkers of the Epidermal Growth Factor Receptor (EGFR)
Current Topics in Medicinal Chemistry Strategies for Design of Non Peptide CCK1R Agonist/Antagonist Ligands
Current Topics in Medicinal Chemistry Systemic Treatment of Advanced Biliary Tract Carcinoma: Emerging Roles of Targeted Therapy and Molecular Profiling
Clinical Cancer Drugs Human Exfoliated Deciduous Teeth Stem Cells: Features and Therapeutic Effects on Neurogenerative and Hepatobiliary-pancreatic Diseases
Current Stem Cell Research & Therapy Ezetimibe; More Than a Low Density Lipoprotein Cholesterol Lowering Drug? An Update After 4 Years
Current Vascular Pharmacology ABC Transporters, Bile Acids, and Inflammatory Stress in Liver Cancer
Current Pharmaceutical Biotechnology The Clinical Significance of Indocyanine Green Excretion Test in Evaluation of Liver Functional Reserve
Current Signal Transduction Therapy Liposomal Irinotecan in the Treatment of Refractory Pancreatic Cancer
Recent Patents on Anti-Cancer Drug Discovery The Synthesis, Anticancer Activity, Structure-Activity Relationships and Molecular Modelling Studies of Novel Isoindole-1,3(2H)-dione Compounds Containing Different Functional Groups
Anti-Cancer Agents in Medicinal Chemistry Potential of Liposomes for Enhancement of Oral Drug Absorption
Current Drug Delivery Molecular Imaging of Apoptosis In Vivo with Scintigraphic and Optical Biomarkers – A Status Report
Anti-Cancer Agents in Medicinal Chemistry The Role of Orexin System in Antipsychotics Induced Weight Gain
Current Psychiatry Reviews Proteomics and Protein Analyses of Ovine and Caprine Body Fluids: Current Studies and Future Promises
Current Protein & Peptide Science The Functional Role of Long Non-coding RNA UCA1 in Human Multiple Cancers: a Review Study
Current Molecular Medicine Somatostatin and Octreotide on the Treatment of Acute Pancreatitis - Basic and Clinical Studies for Three Decades
Current Pharmaceutical Design Decreased lncRNA SNHG16 Accelerates Oxidative Stress Induced Pathological Angiogenesis in Human Retinal Microvascular Endothelial Cells by Regulating miR-195/mfn2 Axis
Current Pharmaceutical Design Redox Homeostasis, Bioactive Agents and Transduction Therapy
Current Signal Transduction Therapy Liver Transporters in Hepatic Drug Disposition: An Update
Current Drug Metabolism Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Prophylaxis of Cancer
Current Cancer Therapy Reviews